てんかんイベントに対するバイオマーカーを標的とした刺激 (BTSEE)
てんかんにおけるバイオマーカーを標的とした刺激の安全性と有効性
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:David Himes, BSEE
- 電話番号:425-679-9505
- メール:dhimes@cadenceneuro.com
研究場所
-
-
California
-
Palo Alto、California、アメリカ、94304
- 募集
- Lucile Packard Children's Hospital Stanford
-
コンタクト:
- Swetapadma Patnaik
- 電話番号:(650) 721-1458
- メール:sweta@stanford.edu
-
主任研究者:
- Ann Hyslop Segeren, MD
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
コンタクト:
- Karla Crockett
- 電話番号:507-538-9140
- メール:Crockett.Karla@mayo.edu
-
主任研究者:
- Nicholas Gregg, MD
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- Cook Children's Medical Center
-
コンタクト:
- Mariana Gallardo
- 電話番号:682-303-4916
- メール:Mariana.Gallardo@cookchildrens.org
-
主任研究者:
- M. Scott Perry, MD
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- 募集
- Seattle Children's Hospital
-
主任研究者:
- Hannah Goldstein, MD
-
コンタクト:
- Deborah Grenard
- 電話番号:206-987-8078
- メール:Cadence@seattlechildrens.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subject is greater than or equal to 7 years of age.
- Subject has focal onset seizures.
- Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
- Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
- Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
- For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
- Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
- A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
- Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
- Subject has had a brain MRI epilepsy evaluation within the past two years.
- Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.
Exclusion Criteria:
-
Subject has a history of substance abuse within the preceding two years.
-
Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
-
Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
-
Subject has anatomy that may interfere with electrode placement.
-
Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
-
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
-
Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
-
Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
-
Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
-
Subject has primary generalized seizures.
-
Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
- The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
- Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
-
Subject, in the opinion of the Investigator, would be a poor study candidate.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:処理
|
Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse event rate
時間枠:Intervals through 7, 12, and 24 months post-implant
|
Determine adverse event rate, including adverse device effects and serious adverse events |
Intervals through 7, 12, and 24 months post-implant
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Seizure frequency
時間枠:Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline. |
Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
|
Neurocognitive testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Depression testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Anxiety testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Quality of life testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Sleep testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Seizure severity testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Caregiver burden testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Suicidality risk testing
時間枠:Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25.
- Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20.
- Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6.
- Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283.
- Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。